Search research articles
Contact Us
Filters
Showing results (1-10 of 174) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2015
Tumor Genetic Screening Programs: A Call to Action
David M Hyman, David B Solit
JAMA
|
January 26, 2012
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer
David M Hyman, David R Spriggs
Cancer Discovery
|
June 4, 2017
Quantifying the Benefits of Genome-Driven Oncology
Alison M Schram, David M Hyman
Nature
|
November 15, 2019
A view on drug resistance in cancer
Neil Vasan, José Baselga, David M Hyman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer
Alison M Schram, Alexia Iasonos, David M Hyman
Clinical Advances in Hematology & Oncology : H&O
|
June 14, 2014
Targeted therapies for treatment of recurrent ovarian cancer
Rachel N Grisham, David M Hyman, Gopa Iyer
Cell
|
February 11, 2017
Implementing Genome-Driven Oncology
David M Hyman, Barry S Taylor, José Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2016
Reply to M.P. Decatris et al
David M Hyman, David B Solit, Alexia Iasonos
Current Opinion in Oncology
|
May 21, 2014
Management of advanced uterine leiomyosarcoma
David M Hyman, Rachel N Grisham, Martee L Hensley
Oncology
|
October 12, 2011
Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature
David M Hyman, Gerald A Soff, Lewis J Kampel
Page
of 18
Search research articles
Search
Showing results (1-10 of 174) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2015
Tumor Genetic Screening Programs: A Call to Action
David M Hyman, David B Solit
JAMA
|
January 26, 2012
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer
David M Hyman, David R Spriggs
Cancer Discovery
|
June 4, 2017
Quantifying the Benefits of Genome-Driven Oncology
Alison M Schram, David M Hyman
Nature
|
November 15, 2019
A view on drug resistance in cancer
Neil Vasan, José Baselga, David M Hyman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer
Alison M Schram, Alexia Iasonos, David M Hyman
Clinical Advances in Hematology & Oncology : H&O
|
June 14, 2014
Targeted therapies for treatment of recurrent ovarian cancer
Rachel N Grisham, David M Hyman, Gopa Iyer
Cell
|
February 11, 2017
Implementing Genome-Driven Oncology
David M Hyman, Barry S Taylor, José Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2016
Reply to M.P. Decatris et al
David M Hyman, David B Solit, Alexia Iasonos
Current Opinion in Oncology
|
May 21, 2014
Management of advanced uterine leiomyosarcoma
David M Hyman, Rachel N Grisham, Martee L Hensley
Oncology
|
October 12, 2011
Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature
David M Hyman, Gerald A Soff, Lewis J Kampel
Page
of 18